Evidence map›Paper›PMID 32676990›Full record

ArticleMolecular neurobiology2020

Extracellular Vesicles of Alzheimer's Disease Patients as a Biomarker for Disease Progression.

Anat Aharon, Polina Spector, Rawan Sayed Ahmad, Nizar Horrany, Annie Sabbach, Benjamin Brenner, Judith Aharon-Peretz

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication.medRxiv : the preprint server for health sciences · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anat AharonTel Aviv Sourasky Medical Center, Tel-Aviv, Israel. anataha@tlvmc.gov.il.ORCID http://orcid.org/0000-0002-8297-0128
Polina SpectorCognitive Neurology Unit, Rambam Health Care Campus, Haifa, Israel.
Rawan Sayed AhmadTel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Nizar HorranyCognitive Neurology Unit, Rambam Health Care Campus, Haifa, Israel.
Annie SabbachDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Benjamin BrennerDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Judith Aharon-PeretzBruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Rambam Health Care Campus · ILTechnion – Israel Institute of Technology · ILTel Aviv Sourasky Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative brain pathology and the most common form of dementia. Evidence suggests that extracellular vesicles (EVs) containing cytokines and microRNA are involved in inflammation regulation. The current study aimed to explore a potential impact of AD patients' EVs on disease progression. Blood samples were collected after obtaining signed informed consent (No. 0462-14-RMB) from 42 AD patients at three stages of disease severity and from 19 healthy controls (HC). EV size and concentration were studied by nanotracking analysis. EV membrane antigens were defined by flow cytometry and Western blot; EV protein contents were screened by protein array; the miRNA content was screened by nanostring technology and validated by RT-PCR. HC and AD patients' EVs consisted of a mixture of small (< 100 nm) and larger vesicles. The myelin oligodendrocyte glycoprotein (MOG) expression on EVs correlated with disease severity. EVs of patients with moderate and severe AD had significantly higher levels of MOG, compared with mild AD patients. Levels of EVs expressing the axonal glycoprotein CD171 were significantly higher in severe AD patients than in HC. Increase in endothelial EVs was observed in AD patients. An above twofold increase was found in the content of inflammatory cytokines and > 50% decrease in growth factors in AD patients' EVs compared with HC-EVs. Levels of let-7g-5p, miR126-3p, miR142-3p, miR-146a-5p, and mir223-3p correlated with disease severity. Neural damage, specific miRNA downregulation, and inflammatory cytokine upregulation, found in patients' EVs, might be used as a biomarker reflecting AD severity.

Indexed as

Disease ProgressionAgedAlzheimer DiseaseBiomarkersCytokinesExosomesExtracellular VesiclesFemaleGene Expression RegulationHumansIntercellular Signaling Peptides and ProteinsMaleMicroRNAsMiddle AgedMyelin-Oligodendrocyte GlycoproteinNeuronsBiomarkersCytokinesIntercellular Signaling Peptides and ProteinsMicroRNAsMyelin-Oligodendrocyte GlycoproteinAlzheimer’s disease (AD)CytokinesExtracellular vesicles (EVs)MicroRNA (miRNA)

Identifiers

PMID32676990
OpenAlexW3043188994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.